PD-L1

    General & Epithelial Markers
    ZR3 Rabbit Monoclonal

    Zeta PD-L1 Antibody.  Zeta’s recombinant rabbit antibody recognizes PD-L1 (Programmed cell death ligand 1), a protein that is overexpressed in human tumors including melanoma, diffuse large B-cell lymphoma, and carcinomas of the lung, bladder, breast, kidney and colon.  Zeta’s PD-L1 antibody (clone ZR3) specifically binds PD-L1, also known as Cluster of Differentiation (CD274) or B7 homolog1 (B7-H1).  PD-L1 is a type 1 transmembrane protein involved in the regulation of cellular and humoral immune responses. The interaction of PD-L1 with its receptor PD-1 provides both stimulatory and inhibitory signals in regulating T cell activation and tolerance during pregnancy, tissue allografts, autoimmune disease and malignant transformation. The binding of PD-L1 to PD-1 induces apoptosis or exhaustion in activated T cells, where blockade of this interaction has been shown to enhance the antitumor activity of T cells.

    In its normal function, PD-L1 is an immune checkpoint protein that regulates the immune response to prevent chronic autoimmune inflammation and is normally expressed on activated immune cells such as antigen presenting cells and B cells.  PD-L1 expression is induced in response to inflammation and high level cytokine expression, where it binds cell surface receptors PD1 and B7 on CD8+ T cells. It is believed that cancers express PD-L1 as an adaptive immune resistance mechanism to attenuate the host antitumor immune response.  As a result, many therapeutic products see to block PD-L1 and PD1 acvity to reactive T cell mediated tumor cell killing.

    Zeta’s PD-L1 antibody provides superior specificity and immunohistochemistry staining patterns.  PD-L1 is positive in a small number of normal tissues (immune cells and tonsil) and in a large number of cancer tissues including non-small cell lung carcinoma, cervical cancer, head and neck squamous cell carcinoma, urothelial carcinoma, triple negative breast cancer, and esophageal squamous cell carcinoma.  Additionally, PD-L1 is often overexpressed in placenta, and many other human tumors such as melanoma, diffuse large B-cell lymphoma, and carcinomas of the lung, bladder, breast, kidney and colon.

    Antibodies to PD-L1 can provide information regarding nonsmall cell lung carcinoma (NSCLC), cervical carcinoma (including cervical squamous cell carcinoma and endocervical adenocarcinoma), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), advanced/metastatic triple negative breast cancer (TNBC), esophageal squamous cell carcinoma (ESCC).

    Visit PD-L1 LDT | NeoGenomics Laboratories for use case for ZR3, Zeta’ PD-L1 rabbit recombinant monoclonal antibody.

    Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists.  Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.

    Specifications
    Species Reactivity:Humans; others not tested
    Known Applications:Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
    Supplied As:Buffer with protein carrier and preservative
    Storage:Store at 2ºC to 8ºC
    Control:Placenta or lung adenocarcinoma
    Visualization:Membrane
    Isotype:IgG
    Immunogen:KLH-conjugated linear peptide corresponding tohuman PD-L1
    Ordering Information
    Classification IVD
    Catalogue Number Z2002RL
    Classification IVD
    Catalogue Number Z2002RL
    Package Inserts
    IFU-PD-L1 ZR3 - IVDL
    Regulatory Notice
    Product classification varies based on regulations of individual countries. Please contact your local distributor for more information. Products labeled as ASR or RUO in the US might be available as IVD or RUO in respective countries.
    SDS
    SDS